76706-67-7

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Thiazolecarboxylicacid,2-ethyl-,ethylester(9CI) is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity allow it to be incorporated into the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Production:
4-Thiazolecarboxylicacid,2-ethyl-,ethylester(9CI) also serves as an important intermediate in the production of agrochemicals. Its potential to form bioactive molecules makes it valuable in the creation of pesticides, herbicides, and other agricultural products designed to protect crops and enhance agricultural yields.
Used in Antibacterial and Antifungal Applications:
4-Thiazolecarboxylicacid,2-ethyl-,ethylester(9CI) has been studied for its potential antibacterial and antifungal properties. Its ability to combat microbial infections positions it as a candidate for use in the development of new antimicrobial agents, addressing the growing need for effective treatments against drug-resistant pathogens.
Used in Organic Synthesis Reactions:
Due to its ethyl ester form, 4-Thiazolecarboxylicacid,2-ethyl-,ethylester(9CI) can be easily integrated into various organic synthesis reactions. This makes it an important building block for the production of other organic compounds, further expanding its applications across different industries.

Upstream product

• 631-58-3 thiopropanamide 
• 673476-96-5 (2-chloro-phenyl)-thioacetic acid amide 
• 70-23-5 ethyl Bromopyruvate 
• 848555-79-3 2-ethyl-4,5-dihydrothiazole-4-carboxylic acid ethyl ester 
• 868-59-7 L-cysteine ethyl ester hydrochloride 
• 123-38-6 propionaldehyde 

Downstream Products

• 937663-77-9 (2-ethylthiazol-4-yl)methanol 
• 769124-05-2 2-ethylthiazole-4-carboxylic acid 
• 1427954-58-2 ethyl 2-ethyl-5-phenylthiazole-4-carboxylate 
• 76706-66-6 2-ethyl-thiazole-4-carboxylic acid amide 

Relevant academic research and scientific papers

Copper(II)-catalyzed oxidation of 4-carboxythiazolines and 4-carboxyoxazolines to 4-carboxythiazoles and 4-carboxyoxazoles

A mild copper(II)-catalyzed oxidation of 4-carboxythiazolines and 4-carboxyoxazolines to 4-carboxythiazoles and 4-carboxyoxazoles has been developed. Various substrates with alkyl or aryl substitutions at 2-position on azoline ring could be smoothly oxidi

Oxidation of 4-carboxylate thiazolines to 4-carboxylate thiazoles by molecular oxygen

A facile and environment-benign oxidation by molecular oxygen was applied for the conversion of 4-carboxylate thiazolines to 4-carboxylate thiazoles. The substituent effect on thiazoline ring was investigated. It was found that electron-poor group on the thiazoline ring could facilitate the oxidation.

PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES

The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE4 mediated disease state.

SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES

Described herein are antipyschotic compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, -CN, imidazolidin-2-one, phenyl, or tetrazole wherein tetrazole is unsubstituted or substituted with (C1-4) alkyl; R2 is H, halogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, OR6, SR6, NO2, CN, COR6, C(O)OR6, C(OH)R6, CONR7R8, phenyl or (C1-6) alkyl, wherein the (C1-6) alkyl is unsubstituted or substituted with a hydroxy; R3 is hydrogen, (C 1-6)fluoroalkyl , (C3-6) cycloalkyl, (C2-6) alkenyl, phenyl, monocyclic heteroaromatic, bicyclic heteroaromatic, or (C1-4)alkyl wherein (C1-4) alkyl is unsubstituted or substituted with a phenyl; R4 and R5 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR9, SR9, NO2, CN, or COR9; R6 is hydrogen, (C1-6) fluoroalkyl, or (C1-6) alkyl; R7 and R8 are independently hydrogen, or (C1-6) alkyl; R9 is hydrogen, (C1-6) fluoroalkyl, (C1-6) alkyl; Alk is (C1-4) alkylene unsubstituted or substituted with a hydroxy; Y is oxygen, sulfur, SO2, or a bond; X is CH2, C=O, S, O, or SO2; Z is hydrogen, halogen, (C1-6) alkyl, (C1-6)fluoroalkyl, -OH, (C1-6) alkoxy, (C1-6) fluoroalkoxy, (C1-6) alkylthio, (C1-6) acyl, (C1-4)alkylsulfonyl, -OCF3, -NO2, - CN, carboxamido which may be substituted on the nitrogen by one or two (C1-4) alkyl groups, and -NH2 in which one of the hydrogens may be replaced by a (C1-4) alkyl group and the other hydrogen may be replaced by either a (C1-4) alkyl group, a (C1-6) acyl group, or a (C1-4) alkylsulfonyl group; the phenyl of R1, R2 or R3 is independently unsubstituted or substituted with one to three substituents independently selected from Z; the monocyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; the bicyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).

(+)-Cystothiazole G: Isolation and structural elucidation

Palladium-catalyzed cyclization-methoxycarbonylation of (2R,3S)-3-methylpent-4-yne-1,2-diol (6) derived from (2R,3S)-epoxybutanoate 5 followed by methylation gave the tetrahydro-2-furylidene acetate (-)-7, which was converted to the left-half aldehyde (+)-3. A Wittig reaction between (+)-3 and the phosphoranylide derived from the bithiazole-type phosphonium iodide 4 using lithium bis(trimethylsilyl)amide afforded the (+)-cystothiazole G (2), whose spectral data were identical with those of the natural product (+)-2. Thus, the stereochemistry of cystothiazole G (2) was proved to be (4R,5S,6(E)).

A catch-and-release strategy for the combinatorial synthesis of 4-acylamino-1,3-thiazoles as potential CDK5 inhibitors

Two-dimensional libraries of 4-acylamino-1,3-thiazoles 9 were prepared via Curtius rearrangement of 1,3-thiazole-4-carbonyl azides 6, trapping of the intermediate isocyanates with oxime resin, and thermal regeneration of the isocyanates from the washed resin in the presence of nucleophiles. Several compounds proved to be selective inhibitors of CDK5/p25 versus the closely homologous CDK2/cyclin A enzyme, with the best analogue (43) possessing over 100-fold selectivity.

Asymmetric synthesis of 2-alkyl-3-thiazoline carboxylates: Stereochemistry of the MnO2-mediated oxidation of cis- and trans-2-alkyl-thiazolidine-(4R)-carboxylates

The asymmetric synthesis of a series of 3-thiazoline carboxylates, 2, was effected by MnO2 oxidation of the corresponding cis/trans thiazolidines, 1. The stereochemistry of the oxidation reaction was studied using NMR and chiral GC analyses. Compounds 2 were obtained with enantiomeric excesses (e.e.s) in the range of 40-100%.

Chemo- and regioselective synthesis of alkyl-3-thiazoline carboxylates

The synthesis of a series of allyl substituted 3-thiazoline-carboxylates was carried out from the corresponding thiazolidines, by a MnO2-mediated oxidation reaction under mild conditions. The reaction was chemoselective towards the amine-imine oxidation and was also regioselective, affording the unsaturation at the 3-position of the heterocycle.